Visiongain Publishes Periodontal Therapeutics Market Report 2021-2031

22 February 2021

Visiongain has published a new report on Periodontal Therapeutics Market Report 2021-2031: Forecasts By Product (Systemic Antibiotics, and Local Antibiotics), By Type (Gingivitis, Chronic Periodontitis, Aggressive Periodontitis, And Necrotizing Periodontal disease), By Drug Type (Generic, and Branded), By Patient Demographics (Adults, Geriatric, Pediatric, By End User (Hospitals, Homecare, Specialty Clinics, and Others), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies) PLUS Profiles of Leading Manufacturing Companies and Regional and Leading National Market Analysis. PLUS COVID-19 Recovery Scenarios.

Global Periodontal Therapeutics market was valued at US$ xx Million in 2020 and is projected to reach at a market value of US$ xx Million by 2031. North America dominated the global Periodontal Therapeutics market and is projected to witness CAGR of XX% during the first half of the forecast period i.e. 2021 to 2031.

COVID-19 Impact on Periodontal Therapeutics Market
COVID-19 impact through different recovery models such as V-shaped, U-shaped, W-shaped, and L-shaped; has been taken into consideration while estimating and forecasting the Periodontal Therapeutics market. Different recovery scenarios are also included in the report for all the segments and regions/nation. The recovery scenarios based on which market has been forecasted and analysed herein the report are mentioned below:

Market Drivers

Increasing Prevalence of Periodontal Diseases around the World
The burden of periodontal diseases is increasing very rapidly around the world, and it is expected to continuously rising over the forecast period. Periodontal disease is related to the tissues which hold teeth in place. The disease mostly occurs due to oral unhygienic, smoking, diabetes, hormonal changes in girls and women among others. The increasing prevalence is periodontal disease is creating a huge demand for the periodontal therapeutics. Due to which increasing prevalence of periodontal disease around the world is working as a driver for the periodontal therapeutics market.

Market Opportunities

Increasing therapeutic Advancements in Periodontal Therapeutics
The burden of periodontal diseases has guided various leading market players to increase their research and development for periodontal therapeutics. Research and development for new advanced periodontal therapeutics are expected to increase adoption of periodontal therapeutics for the treatment of periodontal disease. Currently, various manufacturers are in the development phase and some have already launched clinical trials for periodontal therapeutics which is expected to fulfil demand and create new opportunities for periodontal therapeutics market.

Growing awareness regarding Periodontal Disease

Governments, international organisations and regulatory authorities in various developing nations are making huge efforts for increasing awareness for diagnosis and treatment of periodontal diseases. Increasing focus on raising awareness for diagnosis and treatment of periodontal diseases is expected to untapped the potential markets in the emerging nations by increasing the diagnosis and treatment rate and increasing public spending towards it. Due to this reason the factor is expected to create various opportunities for the periodontal therapeutics market.

Competitive Landscape

Top companies (Den-Mat Holdings, LLC, Valeant Pharmaceuticals International, Inc., Dexcel Pharma
3M Company) constitute more than XX% share of the global Periodontal Therapeutics market. Other companies profiled in the report include: Oral Science, Kaken Pharmaceutical Co., Ltd., Galderma S.A., OASIS Medical, AFT Pharmaceuticals, I-Med Pharma Inc., Dentsply Sirona, Biohorizons, Zimmer Biomet, Emergent Biosolutions, Inc., and F. Hoffmann-La Roche Ltd. others Some of the key developments are listed below:

● In 2017, Geistlich Pharma started clinical trials for PerioSept, which is a new experimental gel formulation. PerioSept is developed to be used as an adjunctive therapy for periodontitis treatment. Once the therapy is approved by the authority it will help the company widen revenue generation from a market focused product portfolio.

Notes for Editors
If you are interested in a more detailed overview of this report, please send an e-mail to or call her on +44 (0) 20 7549 9987.

About Visiongain
Visiongain is one of the fastest-growing and most innovative independent media companies in Europe. Based in London, UK, Visiongain produces a host of business-to-business reports focusing on the automotive, aviation, chemicals, cyber, defence, energy, food & drink, materials, packaging, pharmaceutical and utilities sectors.

Visiongain publishes reports produced by analysts who are qualified experts in their field. Visiongain has firmly established itself as the first port of call for the business professional who needs independent, high-quality, original material to rely and depend on.

Recent News

Visiongain Publishes Checkpoint Inhibitors for Treating Cancer Market Report 2021-2031

We predict strong revenue growth through to 2031. Our work identifies which organizations hold the greatest potential. Discover their capabilities, progress, and commercial prospects, helping you stay ahead.

29 July 2021


Visiongain Publishes Direct-to-Patient Market Report 2021-2031

Over the last few years, Direct-to-Patient has gained widespread attention. DTP companies offer their customers, who are patients, in this case, all kinds of services.

21 July 2021


Visiongain Publishes Drug Delivery Technologies Market Report 2021-2031

Rising geriatric population, increasing prevalence of chronic and infectious diseases, escalating investment in drug R&D by biopharmaceutical companies, rising demand for advanced drug delivery technologies for chronic treatment are some of the major factors that drive the growth of the global drug delivery technologies market.

20 July 2021


Visiongain Publishes Pharma Contract Sales Market Report 2021-2031

Pharma services companies are widening their service offerings (either organically or inorganically through M&A) to become full-service providers, simplifying their customers’ operations and gaining the maximum share of their outsourcing budgets, driven by the willingness of pharma to reduce the number of outsourcers they use.

14 July 2021